ProShares UltraPro QQQ ETF vs Twist Bioscience Corp — how do they compare? ProShares UltraPro QQQ ETF trades at $81.28 (market cap $38.74B), while Twist Bioscience Corp trades at $159.78 (market cap $10.08B). The key difference: ProShares UltraPro QQQ ETF is far larger — about 3.8× Twist Bioscience Corp's market cap, and ProShares UltraPro QQQ ETF is trading nearer its 52-week high, Twist Bioscience Corp nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold ProShares UltraPro QQQ ETF for 24 Days and Twist Bioscience Corp for 27 Days on average.
| TQQQ | TWST | |
|---|---|---|
Market Cap | $38.74B | $10.08B |
Volume | 65,384,797 | 4,229,037 |
Sector | Leveraged / Inverse | Health |
52-Week High | $87.22 | $205.00 |
52-Week Low | $37.89 | $25.45 |
Typical Hold Time | 24 Days | 27 Days |
Enterprise Value | — | $10.01B |
Signals from Pluang's Aura AI — not financial advice
TQQQ trades at $80.22, down 4.04% today, with a bullish technical signal from moving averages but neutral oscillators. The ETF's 3x leverage amplifies Nasdaq-100 moves, yet hidden costs like financing charges impact returns. Recent news highlights volatility risks and institutional position changes, while support sits at $78 and resistance at $83.
Outlook remains mixed: bullish technicals and AI-driven tech growth offer upside, but leverage decay and market volatility pose significant risks. Investors face amplified losses in downturns, warranting caution despite short-term momentum opportunities.
Twist Bioscience (TWST) trades at $152.05, down 2.31% today but remains near recent highs following a significant rally driven by AI partnerships and strong sector interest. The company shows improving revenue growth ($377M in 2025) but continues to post substantial losses (-$78M net income). Technical indicators show mixed signals with bullish overall sentiment but bearish moving averages, while analyst consensus remains positive with 73% buy ratings.
TWST presents a high-risk, high-reward opportunity with strong growth potential through AI-driven drug discovery partnerships but faces significant execution risks amid persistent profitability challenges. The stock's valuation appears stretched given current fundamentals, requiring successful commercialization of pipeline assets to justify premium multiples.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
TQQQ is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to three times (3x) the daily performance of the Nasdaq-100 Index. It is one of the most liquid and actively traded instruments in the market, designed for sophisticated traders to amplify short-term bullish exposure to large-cap non-financial growth stocks, predominantly in the technology and communication sectors.
Read more on TQQQ →Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →